ACTRN12624000715572招募中1 期
A Phase 1, Ascending Dose Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of a SARS-CoV-2 mRNA/LNP Vaccine (HN-0001) in Healthy Adults
HelixNano Australia Pty Ltd0 个研究点目标入组 58 人开始时间: 2024年6月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 58
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Prevention
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Participants are eligible for enrolment in the study only if all the following criteria are met at the time of screening:
- •1. Healthy male or female between the ages of 18 and 65 years (inclusive) at the time of screening. Healthy status will be determined by the Investigator based on the medical history, clinical laboratory results, vital sign and electrocardiogram measurements, and physical examination at screening.
- •2. Participants willing and able to give personal signed informed consent and comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures, including storage of blood samples for secondary use in research.
- •3. Has received at least one vaccination against COVID-19 (most recent dose was received >180 days prior).
- •4. Negative for SARS-CoV-2 infection as determined by PCR test at screening (visit 1) and rapid antigen test on Day 1 (first-dose/baseline).
- •5. Screening laboratory values must be within the laboratory reference ranges or meets the definition of a less than or equal to Grade 1 abnormality on the toxicity scale and deemed not clinically significant by the Investigator. The prothrombin time, fibrinogen, and activated partial thromboembolism (aPPT) must be in the reference range.
- •6. Females must not be pregnant or lactating, or trying to become pregnant as demonstrated by either one of the following A or B:
- •A. Not of child bearing potential: surgically sterile (at least six weeks post bilateral salpingectomy, bilateral oophorectomy, or hysterectomy); or post-menopausal (history of >12 consecutive months without menses prior to Day 1 in the absence of other pathologic or physiologic causes and confirmed by follicle stimulating hormone [FSH] level >40 mIU/mL.
- •B. Women of childbearing potential who are not planning to be pregnant and/or lactating from screening until at least 30 days after vaccination and who meet all of criteria i-iii:
- •(i). Negative serum pregnancy test at the screening visit, and negative serum or urine pregnancy test at baseline (Day 1).
- •(ii). Is not lactating.
- •(iii). Using ne of the following highly effecting methods of contraception:
- •- Combine oestrogen and progesterone, or progesterone-only hormonal contraception associated with inhibition of ovulation (e.g.: implants, pills, patches) initiated >30 days prior to study Day 1/baseline.
- •- Intrauterine device (IUD) or intrauterine system (IUS) inserted >30 days prior to study Day 1/baseline.
- •- Vasectomised partner (the vasectomised partner should have had the procedure at least 6 months prior to Day 1/baseline and be the sole partner for that subject.
- •For male participants that have not had a vasectomy (at least 6 months prior to Day 1/baseline), they must agree to use either a barrier method of contraception from the time of vaccination until at least 90 days after vaccination. Note: female partners (that are of childbearing potential) of male participants (that have not had a vasectomy) should use one of the effective contraceptive methods (e.g.: hormonal contraception, IUD, IUS, or barrier type). Also, male participants must not donate sperm for the duration of 90 days after vaccination.
- •Note: Contraception requirements do not apply for participants in an exclusively same-sex relationship.
排除标准
- •Participants meeting any of the following criteria at the time of screening will be excluded from enrolment:
- •1. Any concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the Investigator or Sponsor, pose an unacceptable risk to the participant in the study or interfere with the interpretation of study data.
- •2. Has had a confirmed SARS-CoV-2 infection within the 6 months before vaccine administration.
- •3. Has an acute illness, as determine by the site PI or delegate, with or without fever (temperature >38 degrees Centigrade [100 degrees Fahrenheit]) 48 hours prior to vaccination.
- •4. Has a history of hypersensitivity or severe allergic reaction to any previous licensed or unlicensed vaccines or component thereof.
- •5. Received immunoglobulins and/or any blood or blood products within the 6 months before vaccine administration.
- •6. Has any blood dyscrasia or any significant disorder or coagulation.
- •7. Has any abnormality or permanent body art (e.g.: tattoo) that would interfere with the ability to observe local reactions at the injection site (deltoid region).
- •8. Received or plans to receive any licensed vaccine within 4 weeks or after vaccination.
- •9. Receipt of any other SARS-CoV-2 or other experimental COVID vaccine within 180 days before vaccination or any planned receipt during the study duration.
研究者
相似试验
撤回
1 期
A study to test the safety of HN-0001 SARS-CoV-2 'COVID-19' Vaccine in Healthy Adults - Cohort 3SARS-CoV-2 (COVID-19)Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12624000719538HelixNano Australia Pty Ltd20
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 3)This study is for healthy volunteers. The intended use of the investigational product is the treatment of serious gram-positive bacterial infectionsInfection - Studies of infection and infectious agentsACTRN12613001212741CPR Pharma Services24
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 2)This study is for healthy volunteers. The intended use of the investigational product is the treatment of serious gram-positive bacterial infectionsInfection - Studies of infection and infectious agentsACTRN12613001211752CPR Pharma Services12
尚未招募
1 期
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MRX-I Tablets in Healthy Adult Subjects (Part 1)This study is for healthy volunteers. The intended use of the investigational product is the treatment of serious gram-positive bacterial infectionsInfection - Other infectious diseasesACTRN12613001206718CPR Pharma Services30
未知
1 期
Phase I Study of TAS-115 in Patients with Advanced Solid TumorsPatients with advanced solid tumorJPRN-jRCT2080221605Taiho Pharmaceutical Co., Ltd.85